Form 4 for CLDX Celldex Therapeutics, Inc.

Accepted 2021-08-09 00:00:00 ET · period of report 2021-08-05 · accession 0001179110-21-008010 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-08-09	2021-08-05	CLDX	Marucci Anthony S	Pres, CEO, Dir	M - OptEx	$42.00	+3,537	27.2K	+15%	+$148.6K
D	2021-08-09	2021-08-05	CLDX	Marucci Anthony S	Pres, CEO, Dir	M - OptEx	$0.00	-3,537	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-08-05	M	A	3,537	$42.00	27,231	D	—	—	(F2) This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021. (F1) Includes 4,256 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Option Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
2	Derivative	Incentive Stock Option	2021-08-05	M	D	3,537	$0.00	0	D	$42.00 · — to 2021-08-05	3,537 Common Stock	(F2) This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021. (F3) As of August 5, 2015, the option is fully vested.